A Prospective, Randomized Multicenter Clinical Trial of the TricValve® Transcatheter Bicaval Valve System in Subjects With Severe Tricuspid Regurgitation.

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 780 participants.

Also called NCT06458907

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 780 participants (planned count) (from the registry)
Sponsor
P+F Products + Features USA Inc. (from the registry)
Registry
  • NCT NCT06458907
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06458907. Randomized; no masking; primary purpose treatment. Start 2026-11 (anticipated); primary completion 2028-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Prospective, Randomized Multicenter Clinical Trial of the TricValve® Transcatheter Bicaval Valve System in Subjects With Severe Tricuspid Regurgitation.
Acronym
TRICAV-II
Condition
Tricuspid Valve Disease
Condition
Heart Valve Diseases
Condition
Cardiovascular Diseases
Condition
Heart Failure
Condition
Tricuspid Valve Regurgitation
Condition
Tricuspid Valve Insufficiency
Intervention (Device)
TricValve System
Intervention (Drug)
Optimal medical therapy
Lead sponsor
P+F Products + Features USA Inc. (class: industry)
Collaborator
Meditrial USA Inc. (class: industry)

Record details

Record id
cardio:ct-nct06458907
Content hash
63f0e332ff130330fab97be837344bb7558e4170851573e8822cda25af044a9b